BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31767470)

  • 1. Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy.
    Bütof R; Löck S; Soliman M; Haase R; Perrin R; Richter C; Appold S; Krause M; Baumann M
    Radiother Oncol; 2020 Feb; 143():44-50. PubMed ID: 31767470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
    Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From CHART to CHARTWEL in non-small cell lung cancer: clinical radiobiological modelling of the expected change in outcome.
    Bentzen SM; Saunders MI; Dische S
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):372-81. PubMed ID: 12555876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neo-adjuvant chemotherapy followed by either continuous hyper-fractionated accelerated radiation therapy week-end less or conventional chemo-radiotherapy in locally advanced NSCLC-A randomised prospective single institute study.
    Kumar R; Kumar HS; Paramanandhan M; Purohit R; Sharma N; Jakhar SL; Sharma S; Maharia S; Rai RK
    J Cancer Res Ther; 2020; 16(4):860-866. PubMed ID: 32930131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.
    Bradley J; Deasy JO; Bentzen S; El-Naqa I
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1106-13. PubMed ID: 15001251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and dosimetric predictors of radiation-induced esophageal toxicity.
    Maguire PD; Sibley GS; Zhou SM; Jamieson TA; Light KL; Antoine PA; Herndon JE; Anscher MS; Marks LB
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):97-103. PubMed ID: 10477012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial.
    Soliman M; Yaromina A; Appold S; Zips D; Reiffenstuhl C; Schreiber A; Thames HD; Krause M; Baumann M
    Radiother Oncol; 2013 Mar; 106(3):299-304. PubMed ID: 23333018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
    Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
    Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer.
    Grant JD; Shirvani SM; Tang C; Juloori A; Rebueno NC; Allen PK; Chang JY
    Pract Radiat Oncol; 2015; 5(4):e383-91. PubMed ID: 25731965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volumetric parameters and prediction of severe acute esophagitis in patients with locally-advanced non small-cell lung cancer treated with neoadjuvant concurrent hyperfractionated-accelerated chemoradiotherapy.
    Manapov F; Sepe S; Niyazi M; Belka C; Friedel G; Budach W
    Radiat Oncol; 2013 May; 8():122. PubMed ID: 23680396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfractionated accelerated radiation therapy for non-small cell lung cancer: clinical phase I/II trial.
    Fu XL; Jiang GL; Wang LJ; Qian H; Fu S; Yie M; Kong FM; Zhao S; He SQ; Liu TF
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):545-52. PubMed ID: 9336130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
    Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
    Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
    Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric and clinical predictors of acute esophagitis in lung cancer patients in Turkey treated with radiotherapy.
    Etiz D; Bayman E; Akcay M; Sahin B; Bal C
    Asian Pac J Cancer Prev; 2013; 14(7):4223-8. PubMed ID: 23991980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.